Pressure Offloading Injectible System With the Use of Juvederm Voluma in the Foot (POIS)

• ClinicalTrials.gov Identifier: NCT04103866
• Recruitment Status: Active, not recruiting
• First Posted: September 26, 2019
• Last Update Posted: October 6, 2020
• Sponsor: Schoenhaus, Jodi, DPM
• Information provided by (Responsible Party): Schoenhaus, Jodi, DPM

Study Description

Brief Summary:

The current use of Juvederm Voluma XC is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21. In this particular setting, the intended use of the product Juvederm Voluma XC is to show that the filler works to alleviate stress in high pressure areas in the foot during gait, thus decreasing foot pain and allowing individuals to walk more comfortably.

Condition or disease	Intervention/treatment	Phase
Metatarsalgia; Hyperkeratotic Callus; Corns; Fat Pad Syndrome	Device: Juvederm Voluma	Not Applicable

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 29 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Pressure Offloading Injectible System With the Use of Juvederm Voluma in the Foot
• Actual Study Start Date: November 1, 2019
• Actual Primary Completion Date: April 30, 2020
• Estimated Study Completion Date: January 30, 2021

Arms and Interventions

Arm

Intervention/treatment

Experimental: Pressure Offloading Innersole System; Use of Juvederm Voluma in the foot for fat pad restoration

Device: Juvederm Voluma; Juvederm will be used in various parts of the foot to increase collagen volume and decrease high pressures of stress typically seen as people age. It will serve to promote the following: foot cushioning due to tissue atrophy, increase comfort when walking, decrease gait peak pressures which will decrease stress on bones and soft tissue and heal calluses, skin lesions, etc. It will also decrease the patient need for balancing and offloading by the use of an in-shoe orthotic device that requires a closed shoe system. Many people complain of pain walking barefoot, in high heels and sandals where orthotics are not effective.

Outcome Measures

Primary Outcome Measures :

1. AOFAS [ Time Frame: 12 weeks ]
   The primary endpoint is 12 weeks post injection. The endpoint will be evaluated by the foot and ankle outcome questionnaire for improvement of pain scale scores and ability to return to activity. An improvement that is statistically relevant will be considered an overall total improvement

Secondary Outcome Measures :

1. Less pressure [ Time Frame: 52 weeks ]
   Follow up evaluations: week two, week 24, and week 52. Follow-up evaluation includes: gate pressure mapping with an improvement being a statistically relevant improvement in peek pressure scores before and after treatment

Eligibility Criteria

• Ages Eligible for Study: 40 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: Yes

Criteria

Inclusion Criteria:

• Patient's 40 to 75 years of age
• Foot and ankle disability index of at least 55 (based on the majority of people having moderate difficulty in weight-bearing living) and heavy clinical significance of fat atrophy as evaluated by the principal investigator creating a standard analysis.
• Atrophy of the heel or the ball of the foot will be evaluated in the step wise approach.
• Second a clinical exam by the primary investigator

Exclusion Criteria:

• Patients who do not have high pressure fat pad atrophy
• Patient is being treated for cancer
• Skin infections
• Unhealed or acute foot fractures
• Patients with a decrease in dorsalis pedis or posterior tibial pulses
• Pregnant or breast-feeding
• Patients who have had previous injections with fillers

• Patients with nerve injury or nerve damage to the foot causing symptoms of numbness, tingling, burning, and sharp shooting or stabbing sensations. This criteria shall be determined by a. direct patient feedback. If the patient verbally states that they have numbness tingling burning sharp shooting or stabbing pains in their feet or ankles they will not be included.

  b. Semmes Weinstein Monofilament Testing - Semmes Weinstein monofilament testing will be performed on all patients. The Semmes Weinstein will be performed on the great toe submetatarsal one submetatarsal three submetatarsal five the heel and the dorsum of the foot. If a patient cannot feel the sends Weinstein filament in any of those locations they will be eliminated.

• Active an acute diabetic foot ulceration
• Patients with severe allergies manifested by history of anaphylaxis
• Patients with a history or presence of multiple severe allergies
• Patients with a history of allergies to gram-positive bacterial proteins
• Patients with a history of allergies to lidocaine.

Contacts and Locations

Locations

United States, Florida

Foot, Ankle & Leg Vein Center

Boca Raton, Florida, United States, 33431

Sponsors and Collaborators

Schoenhaus, Jodi, DPM

More Information

• Responsible Party: Schoenhaus, Jodi, DPM
• ClinicalTrials.gov Identifier: NCT04103866
• Other Study ID Numbers: POIS Study 1
• First Posted: September 26, 2019
• Last Update Posted: October 6, 2020
• Last Verified: May 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes

Additional relevant MeSH terms:

Metatarsalgia; Foot Diseases; Musculoskeletal Diseases; Joint Diseases; Pain; Neurologic Manifestations